SecBot SecBot
425 ·Filed Oct 5, 2026

LAB

STANDARD BIOTOOLS INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed1mo ago SEC0001140361-26-038625
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor for the closing of the Microfluidics sale and any updates on the Treeline transaction, as the company continues to execute its strategic consolidation plan. The lack of disclosed deal value limits immediate financial read-through.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.7220
T+0 close · Oct 5, 2026 · via day close
Latest settled
−15.40%
T+20 · $0.6108 · next T+60 in 6w
Vs SPY
−12.23%
α at T+20
Latest observation
−5.49%
T+27 · FF3 residual α
  1. T+0 · Oct 6 $0.7220entry
  2. T+1 · 6w ago −6.00%α −5.76% · $0.6787
  3. T+5 · 5w ago −8.74%α −8.60% · $0.6589
  4. T+20 · 14d ago −15.40%α −12.23% · $0.6108
  5. T+29 · todayOpen
  6. T+60 · in 6w Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. This follows the recent termination of the Multiplex Bio deal and the signing of the Element Biosystems agreement for the Mass Cytometry business, continuing the company's strategic divestiture process.

Key Financial Metrics

Deal Type
acquisition

Key Facts

  • Standard BioTools entered into a definitive agreement to sell its Microfluidics business to ARCHIMED.
  • Transaction expected to close in approximately 30 days, subject to customary closing conditions.
  • No purchase price or financial terms disclosed in the filing.
  • This is the second business divestiture announced within a week, following the Element Biosystems deal for the Mass Cytometry business.
  • The company terminated the prior Multiplex Bio agreement and paid a $1.5 million termination fee.

Financial Impact

Purchase price not disclosed; the deal is part of a broader strategic divestiture program.

revenuecash

Risk Factors

  • Risk that the transaction may not close within the expected 30-day timeframe or at all.
  • Potential for competing offers or termination of the agreement.
  • Uncertainty regarding the financial impact given undisclosed purchase price.

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001140361-26-038625
Document: ef20083295_ex99-1.htm0001140361-26-038625
Document: 0001140361-26-038625-index-headers.html0001140361-26-038625
Document: 0001140361-26-038625-index.html0001140361-26-038625
Document: 0001140361-26-038625.txt0001140361-26-038625

Track record

23 reports on LAB

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Viewing Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 5, 2026